BRAF and non-small cell lung carcinoma: In the perspective of patient management optimization, we finally sought to investigate the putative prognostic role of chemotherapy- vs. immunotherapy-based regimens in our cohort of BRAF mutant NSCLC, excluding those patients treated with first-line targeted agents.